PDGFR

Platelet-derived growth factor receptor

PDGFR (Platelet-derived growth factor receptors) are cell surface tyrosine kinase receptors for members of the platelet-derived growth factor (PDGF) family. PDGF subunits -A and -B are important factors regulating cell proliferation, cellular differentiation, cell growth, development and many diseases including cancer. There are two forms of the PDGFR: PDGFR alpha and PDGFR beta.

PDGFR Inhibitors

(Z)-Orantinib

((Z)-SU6668; (Z)-TSU-68) Cat. No.: HY-10517A

(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of **Flk1/KDR**, **PDGFRβ**, and **FGFR1**, with IC_{50}s of 2.1, 0.008, and 1.2 μM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

10Z-Hymenialdisine

((Z)-Hymenialdisine; Hymenialdisine) Cat. No.: HY-N6794

10Z-Hymenialdisine ((Z)-Hymenialdisine) is a natural bioactive pyrrole alkaloid. 10Z-Hymenialdisine is a pan kinase inhibitor, and has anticancer activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AC710

Cat. No.: HY-13493

AC710 is a potent **PDGFR** inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AC710 Mesylate

Cat. No.: HY-13493A

AC710 Mesylate is a potent **PDGFR** inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AG 1295

Cat. No.: HY-101957

AG 1295 is a selective **platelet-derived growth factor receptor (PDGFR)** tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR whereas not affects the autophosphorylation of the EGF receptor.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AG 370

Cat. No.: HY-116111

AG 370, an indole tyrphostin, is a potent **PDGF**-induced mitogenesis inhibitor (IC_{50} of 20 μM). AG 370 displays weak inhibition of the EGF receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amuvatinib

(MP470; HPK 56) Cat. No.: HY-10206

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: 98.07%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amuvatinib hydrochloride

(MP470 hydrochloride; HPK 56 hydrochloride) Cat. No.: HY-10206A

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Avapritinib

(BLU-285) Cat. No.: HY-101561

Avapritinib (BLU-285) is a highly potent, selective, and orally active **KIT** and **PDGFRA** activation loop mutant kinases inhibitor with IC_{50}s of 0.27 and 0.24 nM for **KIT D816V** and **PDGFRA D842V**, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Axitinib

(AG-013736) Cat. No.: HY-10065

Axitinib is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 0.1, 0.2, 0.1-0.3, 1.6 nM for **VEGFR1**, **VEGFR2**, **VEGFR3** and **PDGFRβ**, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Axitinib 13CD3

(AG-013736 13CD3)

Cat. No.: HY-10065S

Axitinib 13CD3 (AG-013736 13CD3) is a 13C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 0.1, 0.2, 0.1-0.3, 1.6 nM for **VEGFR1**, **VEGFR2**, **VEGFR3** and **PDGFRβ**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

AZD2932

Cat. No.: HY-18179

AZD2932 is a potent and multi-targeted kinase inhibitor **VEGFR2**, **PDGFβ**, **Flt-3** and **c-Kit** with IC_{50}s of 8, 4, 7 and 9 nM in cell assay, respectively.



Purity: 96.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cediranib

(AZD2171)

Cat. No.: HY-10205

Cediranib (AZD2171) is a highly potent, orally available **VEGFR** tyrosine kinase inhibitor with IC_{50}s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.



Purity: 99.58%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Cediranib maleate

(AZD-2171 maleate)

Cat. No.: HY-13049

Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available **VEGFR** inhibitor with IC_{50}s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.



Purity: 99.74%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Chiauranib

(CS2164)

Cat. No.: HY-124526

Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CHIR-124

Cat. No.: HY-13263

CHIR-124 is a potent and selective **Chk1** inhibitor with IC_{50} of 0.3 nM, and also potently targets **PDGFR** and **FLT3** with IC_{50}s of 6.6 nM and 5.8 nM.



Purity: 96.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CP-673451

Cat. No.: HY-12050

CP-673451 is a potent and selective inhibitor of **PDGFR** with IC_{50}s of 10 and 1 nM for PDGFRα and PDGFRβ, respectively.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Crenolanib

(CP-868596)

Cat. No.: HY-13223

Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases **FLT3** and **PDGFRα/β** with K_ds of 0.74 nM and 2.1 nM/3.2 nM, respectively.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DMPQ dihydrochloride

Cat. No.: HY-108627

DMPQ dihydrochloride is a potent and selective inhibitor of human **platelet-derived growth factor receptor β (PDGFRβ)** with an IC_{50} of 80 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dovitinib

(CHIR-258; TKI258)

Cat. No.: HY-50905

Dovitinib (CHIR-258) is an orally active, potent **multi-targeted tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **CSF-1R**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Dovitinib lactate

(CHIR-258 lactate; TKI-258 lactate) Cat. No.: HY-10207

Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: 99.62%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dovitinib lactate hydrate

(TKI258 lactate hydrate; CHIR-258 lactate hydrate) Cat. No.: HY-B0062

Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dovitinib-D8

Cat. No.: HY-50905S

Dovitinib-D8 (CHIR-258-D8) is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ENMD-2076

Cat. No.: HY-10987A

ENMD-2076 is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ENMD-2076 Tartrate

Cat. No.: HY-10987

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 98.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

Famitinib

(SHR1020) Cat. No.: HY-108713

Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of **c-kit**, **VEGFR-2** and **PDGFRβ** with IC_{50} values of 2.3 nM, 4.7 nM and 6.6 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Flumatinib

(HHGV678) Cat. No.: HY-13904

Flumatinib (HHGV678) is an orally available, selective inhibitor of **Bcr-Abl**. Flumatinib inhibits **c-Abl**, **PDGFRβ** and **c-Kit** with IC_{50}s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Flumatinib mesylate

(HHGV678 mesylate) Cat. No.: HY-13905

Flumatinib mesylate (HHGV678 mesylate) is an orally available, selective inhibitor of **Bcr-Abl**. Flumatinib mesylate inhibits **c-Abl**, **PDGFRβ** and **c-Kit** with IC_{50}s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



Purity: 99.97%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 500 mg

Flumatinib-d3

(HHGV678-d3) Cat. No.: HY-13904S

Flumatinib-d3 is deuterium labeled Flumatinib. Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GZD856

Cat. No.: HY-101489

GZD856 formic is a potent and orally active **PDGFRα/β** inhibitor, with IC_{50}s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a **Bcr-Abl**^{T315I} inhibitor, with IC_{50}s of 19.9 and 15.4nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GZD856 formic

Cat. No.: HY-101489A

GZD856 formic is a potent and orally active **PDGFRα/β** inhibitor, with IC_{50}s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a **Bcr-Abl^{T315I}** inhibitor, with IC_{50}s of 19.9 and 15.4nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HG-7-85-01

Cat. No.: HY-15814

HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of **Bcr-Abl**, **PDGFRα**, **Kit**, and **Src kinases**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hypothemycin

Cat. No.: HY-107417

Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for **VEGFR2/VEGFR1**, **MEK1/MEK2**, **FLT-3**, **PDGFRβ/PDGFRα**, and **ERK1/ERK2**, respectively.



Purity: 96.10%
Clinical Data: No Development Reported
Size: 1 mg

IHMT-TRK-284

Cat. No.: HY-146697

IHMT-TRK-284 (Compound 34) is a potent, orally active **type II TRK kinase** inhibitor with IC_{50} values of 10.5, 0.7, and 2.6 nM to **TRKA, B**, and **C** respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ilorasertib

(ABT-348)

Cat. No.: HY-16018

Ilorasertib (ABT-348) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits **Aurora C**, **Aurora B**, and **Aurora A** with IC_{50}s of 1 nM, 7 nM, 120 nM, respectively.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 50 mg, 100 mg

Ilorasertib hydrochloride

(ABT-348 hydrochloride)

Cat. No.: HY-16018A

Ilorasertib (ABT-348 hydrochloride) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits **Aurora C**, **Aurora B**, and **Aurora A** with IC_{50}s of 1 nM, 7 nM, 120 nM, respectively.



Purity: 99.67%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Imatinib

(STI571; CGP-57148B)

Cat. No.: HY-15463

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits **BCR/ABL**, **v-Abl**, **PDGFR** and **c-kit** kinase activity.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

Imatinib D4

(STI571 D4; CGP-57148B D4)

Cat. No.: HY-15463S1

Imatinib D4 (STI571 D4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imatinib Mesylate

(STI571 Mesylate; CGP-57148B Mesylate)

Cat. No.: HY-50946

Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits **c-Kit**, **Bcr-Abl**, and **PDGFR** (IC_{50}=100 nM) tyrosine kinases.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

Imatinib-d8

(STI571-d8; CGP-57148B-d8)

Cat. No.: HY-15463S

Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

JI-101

Cat. No.: HY-16265

JI-101 is an orally available multi-kinase inhibitor of **VEGFR2**, **PDGFRβ** and **EphB4** with potent anti-cancer activity.



Purity: 99.43%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

JNJ-10198409

Cat. No.: HY-W011266

JNJ-10198409 is a relatively selective, orally active, and ATP competitive **PDGF-RTK** (platelet-derived growth factor receptor tyrosine kinase) inhibitor (IC_{50}=2 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

KG5

Cat. No.: HY-15198

KG5 is an orally active dual **PDGFRβ** and **B-Raf** allosteric inhibitor. KG5 also inhibits **Flt3**, **KIT** and **c-Raf**. KG5 has anticancer, antiangiogenic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ki20227

Cat. No.: HY-10408

Ki20227 is an orally active and highly selective **c-Fms tyrosine kinase (CSF1R)** inhibitor with IC_{50}s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, **VEGFR2** (vascular endothelial growth factor receptor-2), **c-Kit** (stem cell factor receptor) and **PDGFRβ** (platelet-derived growth factor...



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Lenvatinib

(E7080)

Cat. No.: HY-10981

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib mesylate

(E7080 mesylate)

Cat. No.: HY-10981A

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib-d4

(E7080-d4)

Cat. No.: HY-10981S

Lenvatinib-d4 (E7080-d4) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lenvatinib-d5

(E7080-d5)

Cat. No.: HY-10981S1

Lenvatinib-d5 (E7080-d5) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Linifanib

(ABT-869; AL-39324)

Cat. No.: HY-50751

Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of **VEGFR** and **PDGFR** family with IC_{50}s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity.



Purity: 99.72%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Masitinib

(AB1010)

Cat. No.: HY-10209

Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Masitinib mesylate

(AB-1010 mesylate) Cat. No.: HY-10209A

Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Methylnissolin

(Astrapterocarpan) Cat. No.: HY-N2484

Methylnissolin (Astrapterocarpan), isolated from Astragalus membranaceus, inhibits **platelet-derived growth factor (PDGF)**-BB-induced cell proliferation with an IC_{50} of 10 μM.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Multi-kinase inhibitor 1

Cat. No.: HY-103032

Multi-kinase inhibitor 1 is a potent **multi-kinase** inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of **PDGF-R**, **c-Kit** and **Bcr-abl**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Multi-kinase-IN-1

Cat. No.: HY-146014

Multi-kinase-IN-1 (Compound 11k) is a potent **kinase** inhibitor with antitumor activity. Multi-kinase-IN-1 induces cell **apoptosis**, and can be studied for **colorectal cancer**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-(p-Coumaroyl) Serotonin

Cat. No.: HY-129440

N-(p-Coumaroyl) Serotonin is a polyphenol isolated from the seeds of safflower and has antioxidative, anti-atherogenic and anti-inflammatory properties. N-(p-Coumaroyl) Serotonin inhibits PDGF-induced on **phosphorylation of PDGF receptor** and Ca^{2+} release from sarcoplasmic reticulum.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 5 mg

Nintedanib

(BIBF 1120) Cat. No.: HY-50904

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Nintedanib esylate

(BIBF 1120 esylate) Cat. No.: HY-11106

Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Nintedanib-13C,d3

(BIBF 1120-13C,d3) Cat. No.: HY-50904S1

Nintedanib-13C,d3 is the 13C- and deuterium labeled. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nintedanib-d3

(BIBF 1120-d3) Cat. No.: HY-50904S

Nintedanib-d3 (BIBF 1120-d3) is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nintedanib-d8

(BIBF 1120-d8) Cat. No.: HY-50904S2

Nintedanib-d8 is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NVP-ACC789

(ACC-789; ZK202650) Cat. No.: HY-19624

NVP-ACC789 is an inhibitor of human **VEGFR-1**, **VEGFR-2** (mouse **VEGFR-2**), **VEGFR-3** and **PDGFR-β** with IC_{50}s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Orantinib

(SU6668; TSU-68) Cat. No.: HY-10517

Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with K_is of 2.1 μM, 8 nM and 1.2 μM for **Flt-1**, **PDGFRβ** and **FGFR1**, respectively.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pazopanib

(GW786034) Cat. No.: HY-10208

Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with IC_{50}s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pazopanib Hydrochloride

(GW786034 (Hydrochloride)) Cat. No.: HY-12009

Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with an IC_{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pazopanib-d6

(GW786034-d6) Cat. No.: HY-10208S

Pazopanib-d6 (GW786034-d6) is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with IC_{50}s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD-089828

Cat. No.: HY-112345

PD-089828 is an ATP competitive inhibitor of **FGFR-1**, **PDGFR-β** and **EGFR** (IC_{50}s=0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of **c-Src** tyrosine kinase (IC_{50}=0.18 μM). PD-089828 also inhibits **MAPK** with an IC_{50} of 7.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD-161570

Cat. No.: HY-100434

PD-161570 is a potent and ATP-competitive **human FGF-1 receptor** inhibitor with an IC_{50} of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the **PDGFR**, **EGFR** and **c-Src tyrosine kinases** with IC_{50} values of 310 nM, 240 nM, and 44 nM, respectively.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PDGFR Tyrosine Kinase Inhibitor III

(PDGF Receptor Tyrosine Kinase Inhibitor III) Cat. No.: HY-112412

PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PDGFR-IN-1

Cat. No.: HY-144653

PDGFR-IN-1 (compound 7m) is a potent and orally active **PDGFR** (platelet-derived growth factor receptor) inhibitor, with IC_{50} values of 2.4 and 0.9 nM for **PDGFRα** and **PDGFRβ**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PDGFRα kinase inhibitor 1

Cat. No.: HY-111507

PDGFRα kinase inhibitor 1 is a highly selective type II **PDGFRα** kinase inhibitor with IC_{50}s of 132 nM and 6115 nM for PDGFRα and PDGFRβ, respectively.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ponatinib

(AP24534) Cat. No.: HY-12047

Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ponatinib hydrochloride

(AP24534 hydrochloride) Cat. No.: HY-108766

Ponatinib (AP24534) hydrochloride is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ponatinib-d8

(AP24534-d8) Cat. No.: HY-12047S

Ponatinib D8 (AP24534 D8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PP121

Cat. No.: HY-10372

PP121 is a multi-targeted kinase inhibitor with IC_{50}s of 10, 60, 12, 14, 2 nM for **mTOR**, **DNK-PK**, **VEGFR2**, **Src**, **PDGFR**, respectively.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PP58

Cat. No.: HY-18622

PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits **PDGFR**, **FGFR** and **Src** family activities with nanomolar IC_{50} values.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Regorafenib

(BAY 73-4506) Cat. No.: HY-10331

Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1**, respectively.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib Hydrochloride

(BAY 73-4506 hydrochloride) Cat. No.: HY-13308

Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with IC_{50}s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib monohydrate

(BAY 73-4506 monohydrate) Cat. No.: HY-10331A

Regorafenib monohydrate (BAY 73-4506 monohydrate) is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with IC_{50}s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib-13C,d3

(BAY 73-4506-13C,d3) Cat. No.: HY-10331S1

Regorafenib-13C,d3 is the 13C- and deuterium labeled. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Regorafenib-d3

(BAY 73-4506-d3) Cat. No.: HY-10331S

Regorafenib D3 (BAY 73-4506 D3) is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ripretinib

(DCC-2618)

Cat. No.: HY-112306

Ripretinib (DCC-2618) is an orally bioavailable, selective **KIT** and **PDGFRA** switch-control inhibitor.



Purity: 99.33%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sennoside B

Cat. No.: HY-N0366

Sennoside B is an anthraquinone glycoside, found in large quantities in leaves and pods of Senna (Cassia angustifolia). Sennoside B can inhibit PDGF-stimulated cell proliferation by binding to PDGF-BB and its receptor and by down-regulating the PDGFR-beta signaling pathway.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Seralutinib

(GB002; PK10571)

Cat. No.: HY-109190

Seralutinib (GB002) is an inhaled **PDGFRα and PDGFRβ** inhibitor. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension.



Purity: 99.77%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SU 5402

Cat. No.: HY-10407

SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC_{50} of 20 nM, 30 nM, and 510 nM for **VEGFR2**, **FGFR1**, and **PDGFRβ**, respectively.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SU11652

Cat. No.: HY-112452

SU11652 is a potent **receptor tyrosine kinase (RTK)** inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including **VEGFR**, **FGFR**, **PDGFR**, and **Kit**. SU11652 can be uesd for spontaneous cancers expressing Kit mutations research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SU14813

Cat. No.: HY-10501

SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC_{50}s of 50, 2, 4, 15 nM for **VEGFR2**, **VEGFR1**, **PDGFRβ** and **KIT**.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SU14813 maleate

Cat. No.: HY-10501A

SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC_{50}s of 50, 2, 4, 15 nM for **VEGFR2**, **VEGFR1**, **PDGFRβ** and **KIT**.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SU16f

Cat. No.: HY-108628

SU16f is a potent and selective **PDGFRβ** inhibitor with IC_{50}s of 10 nM, 140 nM, 2.29 μM for PDGFRβ, PDGFR1, PDGFR2, respectively.



Purity: ≥99.0%
Clinical Data:
Size: 1 mg, 5 mg

SU4312

Cat. No.: HY-100349

SU4312 is the racemate of (Z)-SU4312 and (E)-SU4312. (Z)-SU4312 inhibits PDGFR and FLK-1 with IC_{50}s of 19.4 and 0.8 μM, respectively. (E)-SU4312 inhibits PDGFR, FLK-1, EGFR, HER-2, and IGF-1R with IC_{50}s of 24.2, 5.2, 18.5, 16.9 and 10.0 μM, respectively.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

SU4984

Cat. No.: HY-118203

SU4984 is a protein tyrosine kinase inhibitor, with an IC_{50} of 10-20 μM for **fibroblast growth factor receptor 1 (FGFR1)**. SU4984 is also inhibits **platelet-derived growth factor receptor**, and **insulin receptor**. SU4984 can be used for the research of cancer.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sunitinib

(SU 11248) Cat. No.: HY-10255A

Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 80 nM and 2 nM for **VEGFR2** and **PDGFRβ**, respectively.



Purity: 98.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Sunitinib Malate

(SU 11248 Malate) Cat. No.: HY-10255

Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 80 nM and 2 nM for **VEGFR2** and **PDGFRβ**, respectively.



Purity: 99.47%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Sunitinib-d10

(SU 11248-d10) Cat. No.: HY-10255AS

Sunitinib D10 (SU 11248 D10) is a deuterium labeled Sunitinib. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 80 nM and 2 nM for **VEGFR2** and **PDGFRβ**, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sunitinib-d4

Cat. No.: HY-10255AS1

Sunitinib-d4 (SU 11248-d4) is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC_{50}s of 80 nM and 2 nM for **VEGFR2** and **PDGFRβ**, respectively.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 1 mg, 25 mg

TAK-593

Cat. No.: HY-15506

TAK-593 is a potent **VEGFR** and **PDGFR** family inhibitor with IC_{50}s of 3.2, 0.95, 1.1, 4.3 and 13 nM for VEGFR1, VEGFR2, VEGFR3, PDFGRα and PDFGRβ, respectively.



Purity: 99.62%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tandutinib

(MLN518; CT53518) Cat. No.: HY-10202

Tandutinib (MLN518) is a potent and selective inhibitor of the **FLT3** with an IC_{50} of 0.22 μM, and also inhibits **c-Kit** and **PDGFR** with IC_{50}s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML).



Purity: 99.48%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg

Tandutinib hydrochloride

(MLN518 hydrochloride; CT53518 hydrochloride) Cat. No.: HY-10202A

Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the **FLT3** with an IC_{50} of 0.22 μM, and also inhibits **c-Kit** and **PDGFR** with IC_{50}s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML).



Purity: 98.84%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg

Telatinib

(Bay 57-9352) Cat. No.: HY-10527

Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of **VEGFR2**, **VEGFR3**, **PDGFα**, and **c-Kit** with IC_{50}s of 6, 4, 15 and 1 nM, respectively.



Purity: 98.72%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Telatinib mesylate

(Bay 57-9352 mesylate) Cat. No.: HY-10527C

Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active **VEGFR2**, **VEGFR3**, **PDGFα**, and **c-Kit** inhibitor with IC_{50}s of 6 nM, 4 nM, 15 nM and 1 nM, respectively.



Purity: 99.46%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TG 100572

Cat. No.: HY-10184

TG 100572 is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TG 100572 Hydrochloride

Cat. No.: HY-10185

TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

TG 100801

Cat. No.: HY-10186

TG 100801 is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: 98.60%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg

TG 100801 Hydrochloride

Cat. No.: HY-10187

TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Toceranib

(SU11654; PHA 291639E)

Cat. No.: HY-10330

Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



Purity: 96.25%
Clinical Data: Launched
Size: 10 mg, 50 mg

Toceranib phosphate

(SU11654 phosphate; PHA 291639E phosphate)

Cat. No.: HY-10330A

Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



Purity: 98.02%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg, 100 mg

Toceranib-d8

Cat. No.: HY-10330S

Toceranib-d8 (SU11654-d8) is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Trapidil

(AR-12008)

Cat. No.: HY-B1016

Trapidil is a vasodilator, is an antiplatelet drug with specific platelet-derived growth factor.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tyrosine kinase-IN-1

Cat. No.: HY-100315

Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 4, 20, 4, 2 nM for **KDR**, **Flt-1**, **FGFR1** and **PDGFRα**, respectively.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyrphostin AG1296

(AG1296)

Cat. No.: HY-13894

Tyrphostin AG1296 is a potent and selective inhibitor of **platelet-derived growth factor receptor (PDGFR)**, with an IC_{50} of 0.8 μM.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyrphostin AG1433

(SU1433; AG1433)

Cat. No.: HY-119757

Tyrphostin AG1433 (SU1433) is a **tyrosine kinases** inhibitor. AG1433 is also a selective **PDGFRβ** and **VEGFR-2 (Flk-1/KDR)** inhibitor with IC_{50}s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vorolanib

(CM082; X-82) Cat. No.: HY-109019

Vorolanib (CM082) is an orally active, potent multikinase **VEGFR/PDGFR** inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895).



Purity: 99.80%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zeteletinib

(BOS-172738; DS-5010) Cat. No.: HY-139590

Zeteletinib (BOS-172738; DS-5010) is an orally active, selective **RET kinase** inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zeteletinib hemiadipate

(BOS-172738 hemiadipate; DS-5010 hemiadipate) Cat. No.: HY-139590A

Zeteletinib (BOS-172738; DS-5010) hemiadipate is an orally active, selective **RET kinase** inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg